HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality

References

• Assembly UG. UN General Assembly High Level Meeting on AIDS. New York, NY, USA, 8–10 June 2011.
   Google Scholar
• Pitisuttithum P. HIV-1 prophylactic vaccine trials in Thailand. Curr. HIV Res. 3(1), 17–30 (2005).
   PubMedGoogle Scholar
• Allers K, Hütter G, Hofmann J et al. Evidence for the cure of HIV infection by CCR5Δ32/32 stem cell transplantation. Blood 117(10), 2791–2799 (2011).
   PubMed Web of Science ®Google Scholar
• Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373(6510), 123–126 (1995).
   PubMed Web of Science ®Google Scholar
• Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100(7), 4144–4149 (2003).
   PubMed Web of Science ®Google Scholar
• Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature 422(6929), 307–312 (2003).
   PubMed Web of Science ®Google Scholar
• Connor RI, Korber BT, Graham BS et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72(2), 1552–1576 (1998).
   PubMed Web of Science ®Google Scholar
• Shibata R, Igarashi T, Haigwood N et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5(2), 204–210 (1999).
   PubMed Web of Science ®Google Scholar
• Hanke T, Samuel RV, Blanchard TJ et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73(9), 7524–7532 (1999).
   PubMed Web of Science ®Google Scholar
• Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296(5572), 1439–1443 (2002).
   PubMed Web of Science ®Google Scholar
• Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391(6665), 397–401 (1998).
   PubMed Web of Science ®Google Scholar
• Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258(5090), 1938–1941 (1992).
   PubMed Web of Science ®Google Scholar
• Baba TW, Liska V, Khimani AH et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med. 5(2), 194–203 (1999).
   PubMed Web of Science ®Google Scholar
• Deacon NJ, Tsykin A, Solomon A et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270(5238), 988–991 (1995).
   PubMed Web of Science ®Google Scholar
• Kent SJ, Dale CJ, Preiss S, Purcell DF. Evidence of recombination between 3’ and 5´ LTRs in macaques inoculated with SIV DNA. AIDS Res. Hum. Retroviruses 18(3), 227–230 (2002).
   PubMedGoogle Scholar
• Robinson HL, Montefiori DC, Johnson RP et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5(5), 526–534 (1999).
   PubMed Web of Science ®Google Scholar
• Learmont JC, Geczy AF, Mills J et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N. Engl. J. Med. 340(22), 1715–1722 (1999).
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al.; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209–2220 (2009).
   PubMed Web of Science ®Google Scholar
• Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191(5), 654–665 (2005).
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A et al.; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881–1893 (2008).
   PubMed Web of Science ®Google Scholar
• Burton DR, Desrosiers RC, Doms RW et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 303(5656), 316 (2004).
   Google Scholar
• Rowland-Jones S, Sutton J, Ariyoshi K et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1(1), 59–64 (1995).
   PubMed Web of Science ®Google Scholar
• Rowland-Jones SL, Dong T, Fowke KR et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102(9), 1758–1765 (1998).
   PubMed Web of Science ®Google Scholar
• Kaul R, Rowland-Jones SL, Kimani J et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J. Clin. Invest. 107(3), 341–349 (2001).
   PubMed Web of Science ®Google Scholar
• Scott-Algara D, Truong LX, Versmisse P et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J. Immunol. 171(11), 5663–5667 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen J. Disappointing data scuttle plans for large-scale AIDS vaccine trial. Science 295(5560), 1616–1617 (2002).
   PubMedGoogle Scholar
• Russell ND, Graham BS, Keefer MC et al.; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a Phase 3 correlates trial. J. Acquir. Immune Defic. Syndr. 44(2), 203–212 (2007).
   PubMed Web of Science ®Google Scholar
• Nitayaphan S, Pitisuttithum P, Karnasuta C et al.; Thai AIDS Vaccine Evaluation Group. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 190(4), 702–706 (2004).
   PubMed Web of Science ®Google Scholar
• Karnasuta C, Paris RM, Cox JH et al.; Thai AIDS Vaccine Evaluation Group, Thailand. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a Phase I/II ALVAC-HIV/AIDSVAX B/E prime–boost HIV-1 vaccine trial in Thailand. Vaccine 23(19), 2522–2529 (2005).
   PubMed Web of Science ®Google Scholar
• Hope TJ. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nat. Med. 17(10), 1195–1197 (2011).
   PubMedGoogle Scholar
• Hessell AJ, Hangartner L, Hunter M et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158), 101–104 (2007).
   PubMed Web of Science ®Google Scholar
• Chung AW, Navis M, Isitman G et al. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol. 24(2), 171–175 (2011).
   PubMedGoogle Scholar
• Chung AW, Navis M, Isitman G et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J. Acquir. Immune Defic. Syndr. 58(2), 127–131 (2011).
   PubMedGoogle Scholar
• Haynes BF, Gilbert PB, McElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366(14), 1275–1286 (2012).
   PubMed Web of Science ®Google Scholar
• Baum LL, Cassutt KJ, Knigge K et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157(5), 2168–2173 (1996).
   PubMed Web of Science ®Google Scholar
• Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 75(15), 6953–6961 (2001).
   PubMed Web of Science ®Google Scholar
• Benson J, Chougnet C, Robert-Guroff M et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J. Virol. 72(5), 4170–4182 (1998).
   PubMedGoogle Scholar
• Sundquist WI, Kräusslich HG. HIV-1 assembly, budding, and maturation. Cold Spring Harb. Perspect. Med. 2(8) (2012).
   PubMedGoogle Scholar
• Piguet V, Sattentau Q. Dangerous liaisons at the virological synapse. J. Clin. Invest. 114(5), 605–610 (2004).
   PubMed Web of Science ®Google Scholar
• Chen P, Hübner W, Spinelli MA, Chen BK. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J. Virol. 81(22), 12582–12595 (2007).
   PubMed Web of Science ®Google Scholar
• Hübner W, McNerney GP, Chen P et al. Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science 323(5922), 1743–1747 (2009).
   PubMed Web of Science ®Google Scholar
• Martin N, Welsch S, Jolly C, Briggs JA, Vaux D, Sattentau QJ. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J. Virol. 84(7), 3516–3527 (2010).
   PubMed Web of Science ®Google Scholar
• Massanella M, Puigdomènech I, Cabrera C et al. Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. AIDS 23(2), 183–188 (2009).
   PubMed Web of Science ®Google Scholar
• Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J. Immunol. 182(2), 1202–1210 (2009).
   PubMed Web of Science ®Google Scholar
• Stratov I, Chung A, Kent SJ. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J. Virol. 82(11), 5450–5459 (2008).
   PubMedGoogle Scholar
• Alter G, Altfeld M. NK cell function in HIV-1 infection. Curr. Mol. Med. 6(6), 621–629 (2006).
   PubMed Web of Science ®Google Scholar
• Alter G, Heckerman D, Schneidewind A et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 476(7358), 96–100 (2011).
   PubMedGoogle Scholar
• Willey S, Aasa-Chapman MM. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol. 16(12), 596–604 (2008).
   PubMedGoogle Scholar
• Naz RK. Female genital tract immunity: distinct immunological challenges for vaccine development. J. Reprod. Immunol. 93(1), 1–8 (2012).
   PubMed Web of Science ®Google Scholar
• Shacklett BL. Cell-mediated immunity to HIV in the female reproductive tract. J. Reprod. Immunol. 83(1–2), 190–195 (2009).
   PubMed Web of Science ®Google Scholar
• Yamada T, Watanabe N, Nakamura T, Iwamoto A. Antibody-dependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface. J. Immunol. 172(4), 2401–2406 (2004).
   PubMedGoogle Scholar
• Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 412(1), 110–116 (2011).
   PubMedGoogle Scholar
• Chung AW, Isitman G, Navis M et al. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc. Natl Acad. Sci. USA 108(18), 7505–7510 (2011).
   PubMed Web of Science ®Google Scholar
• Lambotte O, Ferrari G, Moog C et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23(8), 897–906 (2009).
   PubMed Web of Science ®Google Scholar
• Klein JS, Webster A, Gnanapragasam PN, Galimidi RP, Bjorkman PJ. A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity. AIDS 24(11), 1633–1640 (2010).
   PubMedGoogle Scholar
• Moldt B, Shibata-Koyama M, Rakasz EG et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86(11), 6189–6196 (2012).
   PubMed Web of Science ®Google Scholar
• Battle-Miller K, Eby CA, Landay AL, Cohen MH, Sha BE, Baum LL. Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1-infected women. J. Infect. Dis. 185(4), 439–447 (2002).
   PubMedGoogle Scholar
• Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog. 8(6), e1002739 (2012).
   PubMed Web of Science ®Google Scholar
• Ampol S, Pattanapanyasat K, Sutthent R, Permpikul P, Kantakamalakul W. Comprehensive investigation of common antibody-dependent cell-mediated cytotoxicity antibody epitopes of HIV-1 CRF01_AE gp120. AIDS Res. Hum. Retroviruses 28(10), 1250–1258 (2012).
   PubMedGoogle Scholar
• Ferrari G, Pollara J, Kozink D et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol. 85(14), 7029–7036 (2011).
   PubMed Web of Science ®Google Scholar
• Wren L, Chung A, Kent SJ et al. specific antibody dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology (2012) (In Press).
   Google Scholar
• Holl V, Peressin M, Moog C. Antibody-mediated Fcγ receptor-based mechanisms of HIV inhibition: recent findings and new vaccination strategies. Viruses 1(3), 1265–1294 (2009).
   PubMedGoogle Scholar
• Liu Q, Sun Y, Rihn S et al. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J. Virol. 83(17), 8705–8712 (2009).
   PubMedGoogle Scholar
• Moldt B, Schultz N, Dunlop DC et al. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV. J. Virol. 85(20), 10572–10581 (2011).
   PubMed Web of Science ®Google Scholar
• Forthal DN, Landucci G, Katz J, Tilles JG. Comparison of measles virus-specific antibodies with antibody-dependent cellular cytotoxicity and neutralizing functions. J. Infect. Dis. 168(4), 1020–1023 (1993).
   PubMedGoogle Scholar
• Sung MW, Nagashima S, Johnson JT, Van Dongen GA, Whiteside TL. The role of apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayers of human squamous cell carcinoma of the head and neck targets. Cell. Immunol. 171(1), 20–29 (1996).
   PubMed Web of Science ®Google Scholar
• Surfus JE, Hank JA, Oosterwijk E et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J. Immunother. Emphasis Tumor Immunol. 19(3), 184–191 (1996).
   PubMed Web of Science ®Google Scholar
• Forthal DN, Landucci G. In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J. Immunol. Methods 220(1–2), 129–138 (1998).
   PubMedGoogle Scholar
• Forthal DN, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J. Virol. 80(18), 9217–9225 (2006).
   PubMed Web of Science ®Google Scholar
• Gómez-Román VR, Florese RH, Patterson LJ et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308(1–2), 53–67 (2006).
   PubMed Web of Science ®Google Scholar
• Kantakamalakul W, Pattanapanyasat K, Jongrakthaitae S, Assawadarachai V, Ampol S, Sutthent R. A novel EGFP-CEM-NKr flow cytometric method for measuring antibody dependent cell mediated-cytotoxicity (ADCC) activity in HIV-1 infected individuals. J. Immunol. Methods 315(1–2), 1–10 (2006).
   PubMedGoogle Scholar
• Pollara J, Hart L, Brewer F et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry. A 79(8), 603–612 (2011).
   PubMedGoogle Scholar
• Eller MA, Eller LA, Opollo MS et al. Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine 25(45), 7737–7742 (2007).
   PubMed Web of Science ®Google Scholar
• Gómez-Román VR, Patterson LJ, Venzon D et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174(4), 2185–2189 (2005).
   PubMed Web of Science ®Google Scholar
• Xiao P, Zhao J, Patterson LJ et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 84(14), 7161–7173 (2010).
   PubMed Web of Science ®Google Scholar